Adaptin Bio (APTN) Equity Average (2023 - 2026)

Adaptin Bio's Equity Average history runs 4 years deep, the most recent figure standing at -$1.6 million for Q1 2026.

• In Q1 2026, Equity Average fell 38.65% year-over-year to -$1.6 million; the TTM figure through Mar 2026 stood at -$1.6 million (down 38.65% YoY), while the FY2025 annual figure was -$2.8 million, down 10.08% from the prior year.
• Equity Average came in at -$1.6 million for Q1 2026 at Adaptin Bio, down from -$1.2 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $1.1 million in Q2 2025 to a low of -$3.7 million in Q4 2024.
• A 4-year average of -$997847.2 and a median of -$1.1 million in 2024 frame the typical range for Equity Average.
• Across the five-year window, Equity Average tumbled 5025.92% in 2024 and surged 164.29% in 2025, its largest moves.
• Adaptin Bio's Equity Average stood at -$528150.5 in 2023, then sank by 595.2% to -$3.7 million in 2024, then soared by 67.72% to -$1.2 million in 2025, then plunged by 37.73% to -$1.6 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered -$1.6 million, -$1.2 million, and -$203334.5 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison